3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
24
Hereditary Sensory and Autonomic Neuropathies
6
Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Ovarian Neoplasms
2
Multiple Endocrine Neoplasia Type 1
2
Head and Neck Neoplasms
2
Advanced Breast Cancer
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein
1
Pre-menopausal Breast Cancer
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphatic Abnormalities
1
Lymphangioma, Cystic
1
Lymphangioma
1
Kidney Neoplasms
1
Hyperglycemia
1
HER2-positive Metastatic Breast Cancer
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Advanced or Metastatic ER+ Breast Cancer
1
Advanced and Selected Solid Tumors
1
Advanced Solid Tumors With an Alteration of the PIK3CA Gene
1
Advanced Solid Tumor
1
Advanced HER2+Breast Cancer
1
Interventions
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphatic Abnormalities
×
Alpelisib
×
Clear all
NCT05948943
2026-06-02
EPIK-L1
Novartis
Phase 2/3
Recruiting
232 enrolled